Related Experiment Video

Updated: Jul 4, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

535

Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis

Thomas S Murray1, Gail Stanley2, Jonathan L Koff3

  • 1Department of Pediatrics, Section Infectious Diseases and Global Health, Yale University School of Medicine, PO Box 208064, 333 Cedar Street, New Haven, CT 06520-8064, USA.

Infectious Disease Clinics of North America
|January 27, 2024
PubMed

Insights

Cystic fibrosis patients face persistent multidrug-resistant organism infections. New therapies, including gallium and bacteriophages, show promise but require further clinical trials for optimal use.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Cystic fibrosis (CF) patients are susceptible to respiratory tract infections by multidrug-resistant organisms (MDROs).
  • Despite advances in CFTR modulator therapies, MDRO infections remain a significant clinical challenge.
  • Common CF pathogens include MRSA, Pseudomonas aeruginosa, and nontuberculous mycobacteria (NTM).

Purpose of the Study:

  • To review current and emerging therapeutic strategies for managing MDRO pulmonary infections in CF patients.
  • To highlight the need for novel antimicrobial interventions to combat antibiotic resistance in CF.

Main Methods:

  • Review of existing literature on antimicrobial therapies for CF lung infections.
  • Discussion of pharmacokinetic/pharmacodynamic adjustments, inhaled formulations, and beta-lactam/beta-lactamase combinations.
  • Exploration of innovative approaches like gallium and bacteriophage therapy.

Main Results:

  • Optimizing existing drug regimens and developing inhaled formulations are key strategies.
  • Newer beta-lactam/beta-lactamase combinations offer improved efficacy.
  • Gallium and bacteriophages represent promising alternative treatments for highly resistant infections.

Conclusions:

  • Novel antimicrobial interventions are crucial for treating MDRO infections in CF.
  • Further clinical trials are necessary to establish optimal dosing and efficacy of new strategies.
  • Identifying CF patients who will benefit most from these emerging treatments is essential.
Keywords:
BacteriophageCystic fibrosisGalliumMultidrug-resistant organisms

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.0K
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

505

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
164
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
244
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.9K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
329